Troglitazone and liver injury: In search of answers†
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Troglitazone (TGZ) (Rezulin; Pfizer, Madison, NJ) was withdrawn from the market by the U.S. Food and Drug Administration (FDA) in March 2000, because it was associated with the development of acute liver failure.1 Approximately 35,000 TGZ injury claims are pending within the United States.2 However, even 4 years later, the mechanisms of TGZ-induced liver injury remain highly controversial and poorly understood. A review of the topic proposed that TGZ hepatotoxicity was mediated through the induction of steatosis and apoptosis and that the injury could be silent (without increased serum aminotransferases, bilirubin, or alkaline phosphatase).3 In addition, it has been suggested that TGZ may induce liver injury as a consequence of mitochondrial damage, oxidative stress, or by inhibiting the bile salt excretory protein (Bsep).3 Furthermore, these effects have been attributed, at least in part, to the accumulation of TGZ in the liver, particularly among patients with liver disease, as well as to the peculiar metabolism of the drug.3 Finally, it has been postulated that liver fibrosis and cancer may result from TGZ hepatotoxicity.3 These presumed chronic complications would constitute an extraordinary medical burden to the approximately 1.92 million patients treated with TGZ. Because these alleged long-term complications of TGZ-induced liver injury have significant medical, social, legal, and financial repercussions, this review evaluates the scientific merits of the proposed mechanisms and suggest alternative explanations. TGZ, troglitazone; FDA, Food and Drug Administration; Bsep, bile salt excretory protein; PPAR, peroxisomal proliferator-activated receptor; ALT, alanine aminotransferase; NASH, nonalcoholic steatohepatitis; Cmax, maximal concentration; TNF, tumor necrosis factor. Insulin resistance can result from an inherited defect in mitochondrial oxidative phosphorylation in children of patients with type 2 diabetes4 or from acquired defects in mitochondrial biogenesis,5 which leads to reductions in mitochondrial function, in elderly individuals.6 TGZ, a peroxisomal proliferator-activated receptor (PPAR)-γ agonist that improved insulin resistance, was used for the treatment of type 2 diabetes7, 8 in the United States by approximately 1.92 million patients from March 1997 to March 2000.9 As a consequence of the improved insulin sensitivity,8 TGZ had beneficial cardiovascular effects,10-13 protected pancreatic β-cell function,14 and corrected metabolic abnormalities associated with polycystic ovarian syndrome15 and lipodystrophy.16 In addition, TGZ antagonized the corticosteroid induction of insulin resistance and abnormal glucose tolerance.17 In clinical trials, 1.9% of the subjects who received TGZ and 0.6% of the subjects who received placebo had elevations (≥3 times the upper limit of normal) of serum alanine aminotransferase (ALT) concentrations.18 In this cohort of 2,510 subjects, TGZ induced overt liver injury and jaundice in two individuals.18 A retrospective analysis also concluded that approximately 2% of the patients developed TGZ-induced liver injury judging by the serum ALT elevations.19 By comparison, serum ALT elevations (≥3 times the upper limit of normal) occurred in approximately 25% of subjects taking tacrine,20 a drug that has not been associated with acute liver failure; however, probably fewer than 100,000 patients have been treated with this drug. Unfortunately, 94 of the 1.92 million patients developed liver failure while taking TGZ.1 Although only 49 of these liver failure cases were considered to be possibly or probably related to TGZ,9 the numbers may be higher because of incompleteness of reporting.1 TGZ treatment was associated with a characteristic hepatocellular injury,18, 21-35 with rare instances of either a mixed hepatocellular/cholestatic injury or a predominant cholestatic reaction.36-38 The liver injury associated with TGZ is idiosyncratic39; it is unpredictable, neither time- nor dose-dependent,40 and cannot be reproduced in animals.41-43 Although the mechanism of liver injury induced by TGZ is believed to be a metabolic idiosyncrasy (nonimmunological),39 some of the case reports had histological evidences suggestive of an immunological reaction16, 25, 27, 36 or responded favorably to corticosteroids.28, 38 One of these patients promptly developed a similar destructive, granulomatous cholangitis when treated subsequently with rosiglitazone, a related PPAR-γ agonist,38 supporting the diagnosis of an immunological reaction and suggesting a class effect. According to Zimmerman and Ishak44 and Klatskin and Conn,45 the occurrence of numerous eosinophils or granulomatous inflammatory infiltrates in the liver is sufficiently compelling, albeit circumstantial, evidence that hypersensitivity may play an important role in the injury provoked by TGZ in some patients. Although valuable to the medical and scientific community, neither the MedWatch Reports to the FDA nor the published
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
Micheau, O., & Tschopp, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00521-x · Cited by 2,738
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S., et al. (2003) · Science · doi:10.1126/science.1079368 · Cited by 1,243
Cited by
Vitamin E, antioxidant and nothing more
Traber, M. G., & Atkinson, J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.024 · Cited by 1,478
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Idiosyncratic Drug Reactions: Current Understanding
Uetrecht, J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105150 · Cited by 304
3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies
Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., & Noor, F. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft021 · Cited by 236
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Insight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45
What have we learned from animal models of idiosyncratic, drug-induced liver injury?
Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8
Metadata
- Authors
- Chojkier, M.
- Venue
- Hepatology
- Published
- 2005-02
- Volume
- 41
- Issue
- 2
- Pages
- 237-246
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1981438405
- Cited by
- 125
- References
- 29
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.